Evaluation of the impact of clonal hemopoiesis in patients affected by Multiple Myeloma and...

Updated: about 1 month ago
Deadline: 13 Nov 2020

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (CSE) is the pillar of treatment for patients with Multiple Myeloma (MM), although it can induce clonal hematopoiesis of indetermined potential (CHIP) in CSE or promotes mutated pre-existing clones. These are mutations in genes associated with the development of leukemias (DNMT3A, ASXL1, TP53, TET2), which confer proliferative or survival advantage, with consequent clonal expansion associated with a worse prognosis. The aim of this study is to evaluate the impact of CHIP, performing single cell high resolution
sequencing (NGS) on CD34 + at diagnosis and before transplantation.

View or Apply

Similar Positions